Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Sangamo Therapeutics Second Quarter 2025 Teleconference Call. Please be advised that today's conference is being recorded.
Sangamo Therapeutics Inc (SGMO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Luminus Management Jonathan Barrett And Paul Segal | 250,000 | $168,350 | 0.15% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.69 | 6,784 | $25,028.89 | 32,484 | 2022-06-03 | Filing | |
| $3.60 | 5,000 | $17,996.00 | 48,700 | 2022-06-01 | Filing | |
| $5.20 | 3,000 | $15,585.00 | 13,000 | 2020-03-18 | Filing | |
| $4.99 | 5,000 | $24,950.00 | 30,000 | 2020-03-17 | Filing | |
| $5.67 | 5,000 | $28,350.00 | 25,000 | 2020-03-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.50 | 6,000,000 | $3,000,000.00 | 17,652,466 | 2023-09-26 | Filing | |
| $5.27 | 100,000 | $526,520.00 | 23,652,466 | 2022-08-30 | Filing | |
| $5.33 | 400,000 | $2,130,720.00 | 23,752,466 | 2022-08-29 | Filing | |
| $8.51 | 2,764 | $23,521.92 | 24,152,466 | 2021-12-28 | Filing | |
| $8.56 | 600 | $5,136.00 | 24,155,230 | 2021-12-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,374,728 | $5,071,728 | 0% | |
| 2. | 8,084,419 | $4,376,096 | 0.02% | |
| 3. | 4,808,708 | $2,602,955 | 0% | |
| 4. | 2,332,279 | $1,262,945 | 0% | |
| 5. | 1,281,799 | $693,838 | 0% |
News See All
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy
Sangamo Therapeutics Inc. (NASDAQ:SGMO) is one of the best penny stocks under $1 to buy now.
H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data
Sangamo Therapeutics Inc. (NASDAQ:SGMO) ranks among the best CRISPR stocks to buy. Following the release of Sangamo Therapeutics Inc.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO)
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and welcome to the Sangamo Therapeutics First Quarter 2025 Teleconference Call. Please be advised that today's conference is being recorded.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript March 17, 2025Sangamo Therapeutics, Inc. misses on earnings expectations.
15 Small-Cap Stocks Poised to Outperform in 2025
Fifteen small-cap stocks—predominantly under the technology sector—are taking center stage this year, boasting triple- to quadruple-digit performance in their share prices, thanks to the booming Artificial...
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Sangamo Therapeutics Third Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded.